Pandemic darlings Moderna, BioNTech are now on two different paths
The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find themselves on different paths.
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
BioNTech
since
auto-detected in 8 stories
4 months ago
Family offices ramp up deal-making in June with bets on biotech
A biotech startup backed by former Google CEO Eric Schmidt raised $56 million from investors including the billionaire family office that supported BioNTech.
5 months ago
Covid-19 vaccine-maker BioNTech to acquire former rival CureVac
Both German companies have continued mRNA programs on so-called cancer vaccines.
6 months ago
Stocks making the biggest moves midday: Tesla, BioNTech, DraftKings, Steel Dynamics and more
These are some of the stocks posting the largest moves in midday trading.
8 months ago
This biotech stock is a buy thanks to its cancer treatment pipeline, Citi says
BioNTech has a promising cancer treatment pipeline, per Citi.
10 months ago
Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary
found
Shares of Moderna, BioNTech, Novavax, GSK and Pfizer fell on Tuesday following the vote.
Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary
found
Shares of Moderna, BioNTech, Novavax, GSK and Pfizer fell on Tuesday following the vote.
11 months ago
BioNTech’s boss, Ugur Sahin, remains sanguine about Omicron
Its vaccine may need a tweak, but most important is to speed up booster shots
page 1 of 1